All In Biotech

Investigational drug · Phase 3

Adabelimumab

Also called: SHR-A2102, SHR2554, SHR-1701, Chidamide analog

Not approved by FDA. In 20 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

20

20 still active

All registered trials

1

Any phase or sponsor naming "Adabelimumab"

First trial start

2021

Dec 6, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Adabelimumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Solid Tumors
  • Prostate Cancer
  • Advanced Urothelial Carcinoma
  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer
  • Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
  • HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • Advanced or Metastatic Non-small Cell Lung Cancer
  • Locally Advanced or Metastatic Non-small Cell Lung Cancer
  • Follicular Lymphoma

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Cervical cancer · Oncology · Hematology and blood cancers · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Adabelimumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 28 on PubMed

Also in development for Advanced Solid Tumors

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • AumolertinibSHR-A2009, HS-10296Phase 37 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.